Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.58
EW's Cash to Debt is ranked lower than
59% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. EW: 1.58 )
Ranked among companies with meaningful Cash to Debt only.
EW' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.98 Max: N/A
Current: 1.58
Equity to Asset 0.60
EW's Equity to Asset is ranked lower than
58% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. EW: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
EW' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.60 Max: 0.74
Current: 0.6
0.37
0.74
Interest Coverage 51.73
EW's Interest Coverage is ranked higher than
51% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 50.91 vs. EW: 51.73 )
Ranked among companies with meaningful Interest Coverage only.
EW' s Interest Coverage Range Over the Past 10 Years
Min: 16.5  Med: 59.04 Max: 111.78
Current: 51.73
16.5
111.78
F-Score: 6
Z-Score: 11.10
M-Score: -2.08
WACC vs ROIC
5.85%
31.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 25.86
EW's Operating margin (%) is ranked higher than
96% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. EW: 25.86 )
Ranked among companies with meaningful Operating margin (%) only.
EW' s Operating margin (%) Range Over the Past 10 Years
Min: 13.99  Med: 19.79 Max: 53.09
Current: 25.86
13.99
53.09
Net-margin (%) 19.78
EW's Net-margin (%) is ranked higher than
91% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.77 vs. EW: 19.78 )
Ranked among companies with meaningful Net-margin (%) only.
EW' s Net-margin (%) Range Over the Past 10 Years
Min: 10.36  Med: 15.25 Max: 34.92
Current: 19.78
10.36
34.92
ROE (%) 21.94
EW's ROE (%) is ranked higher than
92% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. EW: 21.94 )
Ranked among companies with meaningful ROE (%) only.
EW' s ROE (%) Range Over the Past 10 Years
Min: 14.26  Med: 19.47 Max: 43.42
Current: 21.94
14.26
43.42
ROA (%) 13.62
EW's ROA (%) is ranked higher than
92% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. EW: 13.62 )
Ranked among companies with meaningful ROA (%) only.
EW' s ROA (%) Range Over the Past 10 Years
Min: 8.72  Med: 12.97 Max: 26.03
Current: 13.62
8.72
26.03
ROC (Joel Greenblatt) (%) 76.92
EW's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. EW: 76.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EW' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 41.35  Med: 53.59 Max: 138.73
Current: 76.92
41.35
138.73
Revenue Growth (3Y)(%) 12.10
EW's Revenue Growth (3Y)(%) is ranked higher than
78% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. EW: 12.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EW' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 11.05 Max: 15.1
Current: 12.1
0
15.1
EBITDA Growth (3Y)(%) 18.70
EW's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. EW: 18.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EW' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 17.20 Max: 57.8
Current: 18.7
0
57.8
EPS Growth (3Y)(%) 21.90
EW's EPS Growth (3Y)(%) is ranked higher than
75% of the 202 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. EW: 21.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EW' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 22.15 Max: 300.9
Current: 21.9
0
300.9
» EW's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

EW Guru Trades in Q2 2015

John Hussman 25,000 sh (New)
Ray Dalio 31,948 sh (New)
Pioneer Investments 201,818 sh (+24.22%)
RS Investment Management 69,285 sh (+16.21%)
Lee Ainslie 1,960 sh (unchged)
PRIMECAP Management 280,000 sh (unchged)
Vanguard Health Care Fund 3,402,670 sh (unchged)
Jeremy Grantham 127,069 sh (-5.22%)
Steven Cohen 173,200 sh (-27.65%)
Ron Baron 379,466 sh (-33.54%)
Joel Greenblatt 110,914 sh (-54.07%)
Jim Simons 290,200 sh (-56.58%)
Paul Tudor Jones 3,800 sh (-96.42%)
» More
Q3 2015

EW Guru Trades in Q3 2015

Louis Moore Bacon 101,319 sh (New)
Frank Sands 1,325,385 sh (New)
RS Investment Management 94,785 sh (+36.80%)
Steven Cohen 233,200 sh (+34.64%)
Jim Simons 361,312 sh (+24.50%)
Paul Tudor Jones 4,529 sh (+19.18%)
Pioneer Investments 202,586 sh (+0.38%)
John Hussman 25,000 sh (unchged)
PRIMECAP Management 280,000 sh (unchged)
Steven Cohen 150,000 sh (unchged)
Ray Dalio Sold Out
Lee Ainslie Sold Out
Jeremy Grantham 124,620 sh (-1.93%)
Ron Baron 353,627 sh (-6.81%)
Vanguard Health Care Fund 2,352,060 sh (-30.88%)
Joel Greenblatt 7,777 sh (-92.99%)
» More
Q4 2015

EW Guru Trades in Q4 2015

Frank Sands 10,924,382 sh (+724.24%)
Pioneer Investments 1,578,222 sh (+679.04%)
Jim Simons 1,105,100 sh (+205.86%)
Paul Tudor Jones 9,847 sh (+117.42%)
PRIMECAP Management 560,000 sh (+100.00%)
John Hussman 50,000 sh (+100.00%)
Ron Baron 664,199 sh (+87.82%)
RS Investment Management 168,325 sh (+77.59%)
Jeremy Grantham 215,118 sh (+72.62%)
Vanguard Health Care Fund 3,217,520 sh (+36.80%)
Louis Moore Bacon 120,000 sh (+18.44%)
Steven Cohen 145,400 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 149,800 sh (-35.76%)
» More
Q1 2016

EW Guru Trades in Q1 2016

Ray Dalio 18,800 sh (New)
Jim Simons 1,665,800 sh (+50.74%)
Pioneer Investments 1,716,295 sh (+8.75%)
RS Investment Management 182,175 sh (+8.23%)
John Hussman 50,000 sh (unchged)
PRIMECAP Management 560,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Louis Moore Bacon Sold Out
Frank Sands 10,172,988 sh (-6.88%)
Ron Baron 528,665 sh (-20.41%)
Jeremy Grantham 149,328 sh (-30.58%)
Paul Tudor Jones 2,600 sh (-73.60%)
Steven Cohen 13,700 sh (-90.85%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:MDT, NYSE:ABT, NYSE:SYK, NYSE:BSX, NYSE:ZBH, NAS:ISRG » details
Traded in other countries:EWL.Germany, EW.Switzerland,
Edwards Lifesciences Corp technologies that treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Edwards Lifesciences Corp was incorporated in Delaware on September 10, 1999. The Company is the manufacturer of heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. It is also a global leader in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. It conducts operations worldwide and are managed in the following geographical regions: United States, Europe, Japan and Rest of World. The products and technologies provided by the Company to treat advanced cardiovascular disease or critically ill patients are categorized into the following main areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Company's Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Company's Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. In the Critical Care portfolio, Edwards Lifesciences' products include pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The Company competes with many companies, including divisions of companies much larger than it and smaller companies that compete in specific product lines or certain geographies. The Company's Surgical Heart Valve Therapy and Transcatheter Heart Valve products are manufactured in California and Utah in the United States, Switzerland, and Singapore. Critical Care products are manufactured primarily in its facilities located in Puerto Rico and the Dominican Republic. The Company's products and technologies are subject to regulation by numerous domestic and foreign government agencies, including the FDA, and various laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of its products and technologies.

Top Ranked Articles about Edwards Lifesciences Corp

Vanguard Sells Out Edwards Lifesciences Company's price and P/E ratio near 10-year highs
Vanguard Heath Care Fund sold out its stake in Edwards Lifesciences Corp. (NYSE:EW) in the first quarter. Read more...
Sands Capital Boosts Stake in Edwards Lifesciences Sands Capital buys nearly 9.6 million shares in 4th quarter
Frank Sands' Sands Capital Management boosted its stake in Edwards Lifesciences (NYSE:EW) in the fourth quarter by adding 9,598,997 shares. Read more...
Weekly 52-Week Highs Highlight: H&R Block, Edwards Lifesciences, Amazon.com, Chubb A summary of companies whose stocks have recently reached their yearly highs
According to GuruFocus list of 52-week highs, H&R Block Inc., Edwards Lifesciences Corp., Amazon.com Inc. and Chubb Corp. have all reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 42.75
EW's P/E(ttm) is ranked lower than
73% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 25.75 vs. EW: 42.75 )
Ranked among companies with meaningful P/E(ttm) only.
EW' s P/E(ttm) Range Over the Past 10 Years
Min: 11.18  Med: 28.06 Max: 50.48
Current: 42.75
11.18
50.48
Forward P/E 31.15
EW's Forward P/E is ranked lower than
85% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 20.75 vs. EW: 31.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 42.57
EW's PE(NRI) is ranked lower than
72% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 26.67 vs. EW: 42.57 )
Ranked among companies with meaningful PE(NRI) only.
EW' s PE(NRI) Range Over the Past 10 Years
Min: 11.16  Med: 28.46 Max: 49.62
Current: 42.57
11.16
49.62
Price/Owner Earnings (ttm) 45.95
EW's Price/Owner Earnings (ttm) is ranked lower than
68% of the 113 Companies
in the Global Medical Devices industry.

( Industry Median: 30.78 vs. EW: 45.95 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
EW' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.55  Med: 28.52 Max: 190.83
Current: 45.95
7.55
190.83
P/B 9.34
EW's P/B is ranked lower than
92% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. EW: 9.34 )
Ranked among companies with meaningful P/B only.
EW' s P/B Range Over the Past 10 Years
Min: 2.9  Med: 4.91 Max: 10.11
Current: 9.34
2.9
10.11
P/S 8.44
EW's P/S is ranked lower than
79% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. EW: 8.44 )
Ranked among companies with meaningful P/S only.
EW' s P/S Range Over the Past 10 Years
Min: 2.32  Med: 4.10 Max: 9.14
Current: 8.44
2.32
9.14
PFCF 46.73
EW's PFCF is ranked lower than
79% of the 91 Companies
in the Global Medical Devices industry.

( Industry Median: 28.14 vs. EW: 46.73 )
Ranked among companies with meaningful PFCF only.
EW' s PFCF Range Over the Past 10 Years
Min: 7.83  Med: 31.01 Max: 593.7
Current: 46.73
7.83
593.7
POCF 37.67
EW's POCF is ranked lower than
82% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 19.95 vs. EW: 37.67 )
Ranked among companies with meaningful POCF only.
EW' s POCF Range Over the Past 10 Years
Min: 7.34  Med: 20.29 Max: 48.77
Current: 37.67
7.34
48.77
EV-to-EBIT 30.99
EW's EV-to-EBIT is ranked lower than
63% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.22 vs. EW: 30.99 )
Ranked among companies with meaningful EV-to-EBIT only.
EW' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 20.20 Max: 39.7
Current: 30.99
6.8
39.7
EV-to-EBITDA 28.23
EW's EV-to-EBITDA is ranked lower than
75% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 17.06 vs. EW: 28.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
EW' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 15.15 Max: 33.5
Current: 28.23
6.4
33.5
PEG 1.52
EW's PEG is ranked higher than
78% of the 72 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. EW: 1.52 )
Ranked among companies with meaningful PEG only.
EW' s PEG Range Over the Past 10 Years
Min: 0.45  Med: 1.35 Max: 3.46
Current: 1.52
0.45
3.46
Shiller P/E 69.55
EW's Shiller P/E is ranked lower than
72% of the 43 Companies
in the Global Medical Devices industry.

( Industry Median: 39.79 vs. EW: 69.55 )
Ranked among companies with meaningful Shiller P/E only.
EW' s Shiller P/E Range Over the Past 10 Years
Min: 34.67  Med: 61.64 Max: 118.59
Current: 69.55
34.67
118.59
Current Ratio 3.97
EW's Current Ratio is ranked higher than
68% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. EW: 3.97 )
Ranked among companies with meaningful Current Ratio only.
EW' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.65 Max: 5.56
Current: 3.97
0.89
5.56
Quick Ratio 3.19
EW's Quick Ratio is ranked higher than
66% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. EW: 3.19 )
Ranked among companies with meaningful Quick Ratio only.
EW' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.04 Max: 4.83
Current: 3.19
0.49
4.83
Days Inventory 181.18
EW's Days Inventory is ranked lower than
67% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. EW: 181.18 )
Ranked among companies with meaningful Days Inventory only.
EW' s Days Inventory Range Over the Past 10 Years
Min: 132.4  Med: 169.19 Max: 206.08
Current: 181.18
132.4
206.08
Days Sales Outstanding 54.52
EW's Days Sales Outstanding is ranked higher than
70% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 69.05 vs. EW: 54.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
EW' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.74  Med: 54.46 Max: 69.95
Current: 54.52
38.74
69.95
Days Payable 43.37
EW's Days Payable is ranked lower than
66% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 62.25 vs. EW: 43.37 )
Ranked among companies with meaningful Days Payable only.
EW' s Days Payable Range Over the Past 10 Years
Min: 33.82  Med: 50.93 Max: 63.34
Current: 43.37
33.82
63.34

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 81.34
EW's Price/Net Current Asset Value is ranked lower than
96% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 6.66 vs. EW: 81.34 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EW' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 10.47  Med: 16.70 Max: 568
Current: 81.34
10.47
568
Price/Tangible Book 14.66
EW's Price/Tangible Book is ranked lower than
89% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. EW: 14.66 )
Ranked among companies with meaningful Price/Tangible Book only.
EW' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.58  Med: 9.40 Max: 199.7
Current: 14.66
5.58
199.7
Price/Projected FCF 2.74
EW's Price/Projected FCF is ranked lower than
66% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. EW: 2.74 )
Ranked among companies with meaningful Price/Projected FCF only.
EW' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.36  Med: 1.93 Max: 3.62
Current: 2.74
1.36
3.62
Price/DCF (Earnings Based) 1.50
EW's Price/DCF (Earnings Based) is ranked higher than
63% of the 19 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. EW: 1.50 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 2.06
EW's Price/Median PS Value is ranked lower than
87% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. EW: 2.06 )
Ranked among companies with meaningful Price/Median PS Value only.
EW' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 0.72 Max: 1.82
Current: 2.06
0.31
1.82
Price/Peter Lynch Fair Value 1.70
EW's Price/Peter Lynch Fair Value is ranked higher than
61% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. EW: 1.70 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
EW' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.59  Med: 1.43 Max: 3.25
Current: 1.7
0.59
3.25
Price/Graham Number 5.26
EW's Price/Graham Number is ranked lower than
84% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. EW: 5.26 )
Ranked among companies with meaningful Price/Graham Number only.
EW' s Price/Graham Number Range Over the Past 10 Years
Min: 1.81  Med: 3.45 Max: 29.59
Current: 5.26
1.81
29.59
Earnings Yield (Greenblatt) (%) 3.20
EW's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. EW: 3.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EW' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 5.00 Max: 14.7
Current: 3.2
2.5
14.7
Forward Rate of Return (Yacktman) (%) 31.03
EW's Forward Rate of Return (Yacktman) (%) is ranked higher than
94% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 6.77 vs. EW: 31.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EW' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 6.4  Med: 21.30 Max: 37.4
Current: 31.03
6.4
37.4

More Statistics

Revenue (TTM) (Mil) $2,601
EPS (TTM) $ 2.34
Beta0.55
Short Percentage of Float1.74%
52-Week Range $62.53 - 112.00
Shares Outstanding (Mil)211.76

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,833 3,224 3,535
EPS ($) 2.70 3.21 3.62
EPS without NRI ($) 2.70 3.21 3.62
EPS Growth Rate
(3Y to 5Y Estimate)
34.48%
» More Articles for EW

Headlines

Articles On GuruFocus.com
Vanguard Sells Out Edwards Lifesciences May 03 2016 
Sands Capital Boosts Stake in Edwards Lifesciences Mar 09 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
15 Best Stocks for Value Investors This Week Feb 15 2016 
Starbucks, Foot Locker Beat the Market Over Past Year Feb 10 2016 
Weekly 52-Week Highs Highlight: H&R Block, Edwards Lifesciences, Amazon.com, Chubb Nov 02 2015 
The Best Companies of the Medical Industry – September 2015 Sep 25 2015 
The Problem with Mechanical Investment Strategies and How You Can Find Your Own Ideas May 27 2015 
Vanguard Health Care Fund's Undervalued Stocks Apr 03 2015 
Fairly Valued Long-Term Performer – Edwards Lifesciences Mar 23 2015 

More From Other Websites
United Parcel Service Inc. (UPS) and EnerSys (ENS) Witness Insider Selling, While 3 Companies... May 27 2016
New Strong Buy Stocks for May 27th May 27 2016
3 Healthcare Stocks at All-Time Highs (ISRG, HSIC) May 25 2016
2 Momentum Health Care Stocks That Will Continue to Outpace the Industry May 25 2016
Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright May 25 2016
Edwards Lifesciences Has a Faulty 'Ticker' May 24 2016
Edwards Lifesciences (EW) Stock Price Target Raised at Canaccord May 23 2016
Stocks End Week On High Note; Chips, Biotechs Power Nasdaq May 20 2016
ETF’s with exposure to Edwards Lifesciences Corp. : May 20, 2016 May 20 2016
S&P 500 to Celebrate One Year of New High: Top ETFs & Stocks May 20 2016
Jury Finds in Favor of CardiAQ in Case with Neovasc May 20 2016
Edwards Lifesciences Corp. breached its 50 day moving average in a Bearish Manner : EW-US : May 20,... May 20 2016
Jury Finds in Favor of CardiAQ in Case with Neovasc May 19 2016
'Mad Money' Lightning Round: Edwards Lifesciences Is Going Higher May 19 2016
Edwards SAPIEN 3 Transcatheter Valve Demonstrates Positive Patient Outcomes At 30 Days In European... May 18 2016
Edwards' Surgical Heart Valve Innovations Demonstrate Positive Patient Benefits May 18 2016
Edwards Lifesciences Presents Positive Data on Sapien3 May 18 2016
Edwards' Surgical Heart Valve Innovations Demonstrate Positive Patient Benefits May 17 2016
Edwards SAPIEN 3 Transcatheter Valve Demonstrates Positive Patient Outcomes At 30 Days In European... May 17 2016
Can Edwards Lifesciences (EW) Stock Continue to Grow Earnings? May 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)